Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 78-88

  Banna, Giuseppe Luigi ^a   Di Maio, Massimo ^b   Follador, Alessandro ^c   Collovà, Elena ^d   Menis, Jessica ^c   Novello, Silvia ^e   Bria, Emilio ^f  

^a CANNIZZARO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d Hospital of Legnano   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant chemotherapy; Non small cell lung cancer; Postoperative radiotherapy; Survey

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH SURVEY; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; HEALTH CARE SURVEYS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; VINBLASTINE;

EID: 79957694798     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.020     Document Type: Article

References (35)

1. Varlotto J.M., Recht A., Flickinger J.C., et al. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer 2009, 115:1059-1069.
2. Chhatwani L., Cabebe E., Wakelee H.A. Adjuvant treatment of resected lung cancer. Proc Am Thorac Soc 2009, 6:194-200.
3. Bordoni R. Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 2008, 13:945-953.
4. Tsuboi M., Ohira T., Saji H., et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007, 13:73-77.
5. Scagliotti G. Multimodality approach to early-stage non-small cell lung cancer. Lung Cancer 2007, 57(Suppl. 2):S6-S11.
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
7. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000, 343:1217-1222.
8. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004, 26:173-182.
9. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003, 95:1453-1461.
10. Strauss G.M., Herndon J.E., Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008, 26:5043-5051.
11. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
12. Arriagada R., Dunant A., Pignon J.P., et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010, 28:35-42.
13. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
14. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
15. Butts C.A., Ding K., Seymour L., et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010, 28:29-34.
16. Douillard JY. Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. J Clin Oncol 2010, 28:3-5.
17. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
18. Bria E., Gralla R.J., Raftopoulos H., et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009, 63:50-57.
19. Miksad R.A., Gonen M., Lynch T.J., Roberts T.G. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. J Clin Oncol 2009, 27:2245-2252.
20. Besse B., Le Chevalier T. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?. J Clin Oncol 2008, 26:5014-5017.
21. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):68-70.
22. http://www.asco.org/ASCOv2/Practice+%2526+Guidelines.
23. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
24. http://www.aiom.it/Attivit%25E0+Scientifica/Linee+guida/Neoplasie+toraco-polmonari/1,349,0.
25. Arriagada R., Auperin A., Burdett S., et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010, 375:1267-1277.
26. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-63.
27. Lally B.E., Zelterman D., Colasanto J.M., et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006, 24:2998-3006.
28. Douillard J.Y., Rosell R., De Lena M., et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008, 72:695-701.
29. Chao C., Studts J.L., Abell T., et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003, 21:4299-4305.
30. Ardizzoni A., Boni L., Tiseo M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
31. Fruh M., Rolland E., Pignon J.P., et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008, 26:3573-3581.
32. Deslauriers J., Gregoire J., Jacques L.F., et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg 2004, 77:1152-1156.
33. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
34. Blanchon F., Grivaux M., Asselain B., et al. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006, 7:829-883.
35. Schleyer T.K.L., Forrest J.L. Methods for the design and administration of web-based survey. Am Med Inform Assoc 2000, 7:416-425.